Raj Devraj simplifies biotech venture evaluation into a four-part framework: scientific viability ("Will it work?"), market viability ("Will it sell?"), feasibility ("Can I do it in my lifetime?"), and execution capability ("Do I have the team?"). This provides a comprehensive yet concise due diligence checklist for early-stage opportunities.
Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.
Early-stage biotechs prioritize scientists to build the core platform. However, once a lead clinical program is identified, the critical hire becomes a Chief Medical Officer who can design the clinical strategy. This hire is timed to the program's maturation, not the company's age, reflecting a pivotal strategic shift.
Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.
To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.
Raj Devraj emphasizes that while intelligence is table stakes, the crucial traits for a startup executive are resilience and "street smarts." This is because navigating the high expectations and intense scrutiny of an investor-heavy private board requires a different skillset than what's found on a resume.